Research conducted by Steven Grant found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The study, published in
Cancer Research, determined that combining the existing drug venetoclax with a class of agents known as a PI3K inhibitors led to synergistic interactions in AML cells stemming from interruption of the function of BCL-2 proteins
and triggering of cell death.